Broker Research reports: Buy reports
for all reports
Latest broker research reports
with
buy recommendations along with target prices forecast and upside.
Browse thousands of reports and search by company.
For Q2FY21, revenue grew by 6% YoY on account of gradual improvement in operations post lockdown. Feed volumes improved 2.5%YoY and Feed realisation grew by 5%YoY due to price hike in previous quarter. However, Processing volumes de-grew by 11%YoY while export realisation grew by 15%YoY due to better region mix. Industry shrimp production is expected to drop by ~15%-20% in FY21 due to Covid-19 led disruptions but to improve in FY22. Relaxation in restrictions and improvement in farm-gate prices is encouraging farmers which along with AFL's increasing market share in Feed segment will support future volumes. We expect...
Glenmark Pharma Ltd (GNP) is an India-based pharmaceutical company with commercial presence in more than 80 countries across the globe. GNP is primarily focused on generics, specialty and OTC businesses. The company has strong regional/country-specific presence in diabetes,...
Net revenue for Q2FY21 declined 14.9% YoY on account of subdued recovery post lockdown relaxations. However, Gross Refinery Margins improved to US$ 5.1/bbl (vs US$ 2.8/bbl in Q2FY20) driven by...
We revise our estimates on gVascepa sales for Dr. Reddy's Laboratories (DRL). Last quarterly sales annualised for Vascepa are US$620mn. We account for upside from Sputnik vaccine in our DRL target price considering the publication of positive data from interim analysis of Phase 3 studies suggesting >95% efficacy at 21 days post administration of the second dose. Revision in our gVascepa Forecasts: We revise our sales forecast on gVascepa for DRL as we gather from recent launch by Hikma that generics have been granted a skinny label, which carves out the larger indication (reduction in CV risk in statin treated patients with TG level >150mg/dl). In addition we also anticipate supply and pricing constraints to restrict the market share. Dr. Reddy is yet to launch...
Laurus Labs' (LAURUS) has acquired 73% stake in Richcore Lifesciences (RICH) for a cash consideration of INR2.5b. The acquisition is a step towards building a vertically integrated biotech segment and adds a new lever to growth. It particularly provides capabilities in high growth areas of Recombinant (Rh)...
EBITDA margin improved 100bps YoY aided by lower employee benefit expenses. In line with operational performance, PAT increased 23.4% YoY to Rs. 3,117cr, further helped by higher other income and lower...
Capital allocation exercise gathered pace in 1HFY21 as MM continued its focus on exiting non core/loss making business. We reiterate BUY on M&M; (MM) led by 1) positive rural sentiments and stable tractor outlook providing margins and cash-flow cushion to compete in UV business, 2) renewed focus to gain back lost market share in UV business with new product launches, 3) dominating presence in LCVs to help ride CV upcycle and 4) increased focus on capital allocation with exit of non-core...
Globally, growth of the enzymes market piggybacks on a diverse spectrum of customer base. This, together with limited number of meaningful players, has created a conducive business environment for existing players in the space. Note that enzymes as cost to percentage of sales is not material, yet its efficacy is very important to end product including constituency of the end product in terms of its taste, appearance, aroma and, thus, quality perception of the products leading to significant supplier stickiness. With a revenue bandwidth of just | 440 crore (~US$60 million) AET remains a...
Earlier, during Q1FY21, VSSL reported a subdued performance. While the Q1FY21 performance was weak on the back of Covid-19 related concerns, in Q2FY21, the company witnessed a healthy turnaround in its operations on the back of a smart recovery in demand from the auto sector. On the back of strong demand from the domestic auto sector, in Q2FY21 VSSL registered its highest ever quarterly sales volume of 43986 tonnes (up 32% YoY). Going forward, for Q3FY21 also, the management expects the healthy trend in auto...
IGL's Q2FY21 revenues declined 23.1% YoY to Rs. 1,441cr with a volume drop of 16.4% YoY to 506 Standard Cubic Meter (SCMmn). This was primarily due to slump in demand of 20.3% for CNG at 255mn kgs (vs. 320mn kgs in Q2FY20) due to transport restrictions. Henceforth, CNG revenues stood at Rs. 944cr down 24.9%. Similarly, demand from industrial and commercial customers were also hit. PNG segment reported sales of Rs. 355cr (-17.1% YoY). Natural Gas and Industrial/ Commercial PNG segment volumes declined 26.1% YoY and 1.4% YoY, respectively, to 34SCMmn and 72SCMmn. This was partially offset by a volume growth of 21.2% YoY in PNG-domestic...
Revenue for Q2FY21 dropped 36.3% YoY to Rs. 549cr primarily as volumes shrank 30.9% YoY to 190.7 Standard Cubic Meter (SCMmn). CNG and PNG Industry/ Commercial volumes declined by 42.0%/19.9% YoY, respectively, as lockdown and transport restrictions extended whereas Domestic PNG increased 21.6% YoY. Despite the impact of COVID-19 during the quarter, MGL achieved a growth in volumes QoQ. Blended volume stood at 2.07SCMmn, led by a strong demand recovery in CNG segment post lockdown (1.28SCMmn - 62% of total volume). Witnessed recovery at 90-95% of pre-COVID levels in Nov'20 as commercial activities gradually kicked off. PNG...
While crude oil prices are witnessing sequential improvements, supported by volume growth from Hazira plant and KG98/2 project in long-run. Hence we upgrade our rating to BUY on the stock with revised target price of Rs. 86 using SOTP valuation....
We have initiating coverage on SOLARA with BUY rating and a target price of Rs 1,350 (P/E of 18x for FY23E earnings) which implies an upside of 25% from the current levels.
Long expected IAC basin trials are on November 27 whereas delivery for the same is expected by December 2021. If things fall in place, as they should, we expect FY22E to be amplified on account of IAC execution. This should aid management to reach their topline target of | 4000 crore. In the quarter, IAC execution was | 491 crore (cost plus | 283 crore, fixed price | 207 crore)....
Steady growth in overall Subscription revenue coupled with recovery from Advertising should support topline growth in the near-term. We remain optimistic of Zee's future growth prospects and reiterate our BUY with target price of Rs. 245 based on 14.5x adj. EPS. Ad spends push up topline, PAT improves sequentially Q2FY21 revenue grew 31.3% QoQ to Rs. 1,723cr (-18.8% YoY) primarily on account of growth strong recovery seen in Advertising revenue at Rs. 903cr (+114% QoQ), as Ad spends see gradual improvement. Subscription revenue also went up 7.5% QoQ...
order book declined 17% YoY to Rs90bn. Management indicated the tendering pipeline remains healthy as the process of ordering continues during 1Q and expects an order inflow of ~Rs15bn for FY21E. Key project such as NRL, Kaveri Basin (few packages), HEML, petrochemical projects, etc. to be awarded in FY21E. HMEL petchem, MRPL expansion, Panipat...
MSS hosted a virtual investor meet (Link for PPT) outlining key strategies to Change in Estimates | Target | Reco achieve for their vision 2025 targets. These include 1) Consol revenues at USD36bn 2) 3CX10 (no country/component/customer contribute >10% in...
Our positive view on MM is based on a strong recovery in Tractors, LCVs recovering in 2HFY21 and positive development on capital allocation. We were not banking on any positive development in its SUV business, but have taken stock of MM's SUV and LCV business in this note. Both businesses have so far positively surprised us. The company is reorienting its SUV business to maintain its DNA and brand position and garner market share. Thar's success shows that it is on the right track. The MM and Ford JV got delayed due to the COVID-19 pandemic. However, the product pipeline reflects some promising upgrades in its UV portfolio....
